India's Suven Pharma up as US FDA completes inspections without observations

Cohance Lifesciences

26/02/2024 04:43

** Shares of Suven Pharmaceuticals  SUVH.NS  up 1.4% at
673.85 rupees
    ** Co says two facilities have completed U.S. FDA
inspections and no Form 483 was issued; form is issued when
violations are observed, per FDA website
    ** Stock on track to end four-day losing streak if trend
holds
    ** Stock surges as much as 5.2% to its highest level in a
month
    ** Since slumping on Feb. 6 after Q3 profit drop, stock has
regained 9.4%

 (Reporting by Varun Vyas in Bengaluru)
 ((varunvyas.hebbalalu@thomsonreuters.com))